Cover Image

美國的MA (醫療事務) 部門的評估:非小細胞肺癌

Medical Affairs Reputations (US) [NSCLC]

出版商 FirstWord 商品編碼 488075
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
美國的MA (醫療事務) 部門的評估:非小細胞肺癌 Medical Affairs Reputations (US) [NSCLC]
出版日期: 2017年03月01日 內容資訊: 英文

本報告依據處理非小細胞肺癌治療藥的主要項12產品的各公司醫療事務 (MA) 團隊相關的100名美國腫瘤專門醫生的調查結果,提供各公司團隊的效能及滿意度的評分及排行榜,醫生的服務利用趨勢,要求,改善點等分析彙整。


  • Avastin (Bevacizumab:Roche)
  • Cyramza (Ramucirumab:Eli Lilly)
  • Gilotrif (Afatinib:Boehringer Ingelheim)
  • Iressa (Gefitinib:AstraZeneca)
  • Keytruda (Pembrolizumab:Merck & Co.)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Portrazza (Necitumumab:Eli Lilly)
  • Tagrisso (Osimertinib:AstraZeneca)
  • Tarceva (Erlotinib:Roche/Astellas Pharma Inc.)
  • Tecentriq (Atezolizumab:Roche)
  • Xalkori (Crizotinib:Pfizer/EMD Serono)
  • Zykadia (Ceritinib:Novartis)


  • 醫生的需求
    • 醫生的MA團隊的利用方法、頻率
    • 認為最重要的服務
    • 最適合的聯繫的頻率和途徑
  • MA隊提供的內容
    • 醫生跟團隊的互動的印象
    • 醫生的團隊效能、滿意度排行榜:12項
    • 與其他團隊的比較
  • 改善需要的地方等

Survey of oncologists shows your medical affairs team may be reaching out too often

If doctors aren't warming up to your medical affairs team as much as you'd like, it may be time to take a step back. Our survey of 100 medical oncologists shows that many of them feel US medical affairs teams for leading NSCLC drugs are contacting them too often. With several teams competing closely, the right approach could make all the difference.

Find out how often you should be reaching out, and what else you can do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (US) .

Comparing 12 major NSCLC treatments from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Merck & Co., Novartis, Pfizer, and Roche, this report reveals:

  • How oncologists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often oncologists want to meet with your team.
  • What you can do to improve your medical affairs services.

You're just a couple of clicks away from actionable information you can use to turn your team into one that doctors rely on.

Top Takeaways

  • Is your team reaching out too often? Survey results show that most teams may be contacting doctors more often than they would like. Find out how often is too often.
  • Competition is close at every level: Rated for overall quality of interactions, teams at the top, middle and bottom of the market are within just a few points of one or more rivals.
  • All teams are turning in a solid performance: EdgeMap performance ratings show that, while the top teams have a slight edge, every team earns a moderately high score from doctors.
  • Satisfaction scores vary: EdgeMap satisfaction scores are moderately high overall, but a handful of teams outscore the rest on all 12 surveyed medical affairs roles.
  • Doctors want actionable information: The five most important roles for medical affairs teams all revolve around providing information doctors can use to make better treatment decisions.
  • There are many other ways teams can improve: More than 80 percent of surveyed doctors had specific suggestions for improving information provision, communication, or continuing medical education (CME) support.

Insight into Medical Affairs Teams for These NSCLC Treatments

  • Avastin (bevacizumab; Roche)
  • Cyramza (ramucirumab; Eli Lilly)
  • Gilotrif (afatinib; Boehringer Ingelheim)
  • Iressa (gefitinib; AstraZeneca)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Portrazza (necitumumab; Eli Lilly)
  • Tagrisso (osimertinib; AstraZeneca)
  • Tarceva (erlotinib; Roche/Astellas Pharma)
  • Tecentriq (atezolizumab; Roche)
  • Xalkori (crizotinib; Pfizer/EMD Serono)
  • Zykadia (ceritinib; Novartis)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams-answering important questions like:

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between February 2nd and 8th, 2017.

Find out what 100 US dermatologists think of your medical affairs team.

Back to Top